Skip to main content
    I

    Inhibrx Biosciences, Inc. (INBX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $77.66
    -5.64 (-6.77%)

    Market Cap: $1.23B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Inhibrx Biosciences, Inc. (INBX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 13, 2026. Financial statements from company filings, amounts in US dollars.

    Inhibrx Biosciences reported revenue of $1.30M for the fiscal year ended Dec 31, 2025, up 550.0% from the year before. That year, net income was -$140.06M with a net margin of -10773.5%, operating cash flow was -$129.79M and free cash flow was -$129.82M. The quarter ended Sep 30, 2026 had revenue of $2.00M and net income of -$38.73M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue fell from $6.67M, a compound annual decline of 16.6%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$1.30M+550.0%100.0%-10386.5%-10773.5%
    Dec 2024$200.00K-88.9%100.0%-165724.0%843786.0%
    Dec 2023$1.80M-17.9%100.0%-12178.9%-13408.9%
    Dec 2022$2.19M-69.2%-4926.7%-5890.4%-6625.3%
    Dec 2021$7.13M-44.4%62.3%-1074.6%-1147.6%
    Dec 2020$12.81M+40.9%-473.8%-526.6%-590.5%
    Dec 2019$9.09M+21.2%-426.9%-480.7%-565.3%
    Dec 2018$7.50M-5.7%-346.1%-393.5%-415.5%
    Dec 2017$7.95M+19.2%-220.9%-248.2%-244.6%
    Dec 2016$6.67MN/A-154.9%-182.2%-124.0%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$1.30M$200.00K$1.80M$2.19M$7.13M$12.81M$9.09M$7.50M$7.95M$6.67M
    Cost of revenue$0$0$0$110.19M$2.69M$73.50M$47.91M$33.45M$25.51M$16.99M
    Gross profit$1.30M$200.00K$1.80M-$107.99M$4.44M-$60.69M-$38.81M-$25.95M-$17.56M-$10.32M
    Research and development$113.03M$203.74M$191.64M$110.19M$71.44M$73.50M$47.91M$33.45M$25.51M$16.99M
    Operating income-$135.03M-$331.45M-$219.22M-$129.12M-$76.56M-$67.44M-$43.71M-$29.51M-$19.73M-$12.15M
    Net income-$140.06M$1.69B-$241.36M-$145.23M-$81.77M-$75.64M-$51.40M-$31.16M-$19.44M-$8.27M
    EBITDA-$130.48M$1.69B-$213.71M-$125.82M-$75.37M-$63.80M-$42.60M-$28.77M-$19.30M-$11.89M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$2.00M$0$0$0$0$1.30M$0$100.00K$0$100.00K$0$1.63M
    Gross profit$2.00M$0$0-$564.00K$0$1.30M$0$100.00K$0$100.00K$0$1.34M
    Operating income-$31.73M-$32.15M-$30.93M-$30.92M-$33.81M-$27.39M-$42.90M-$49.93M-$46.80M-$160.90M-$73.83M-$88.29M
    Net income-$38.73M-$36.65M-$33.44M-$32.83M-$35.26M-$28.65M-$43.31M-$47.87M-$43.86M$1.86B-$78.71M-$93.60M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $102.89M by $21.34M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$146.48M$180.77M$307.89M$290.88M$150.45M$143.74M$26.49M$9.98M$17.25M$21.27M
    Current assets$132.83M$160.40M$295.36M$280.49M$139.11M$132.17M$15.56M$5.66M$15.44M$20.41M
    Cash and equivalents$124.22M$152.60M$277.92M$273.87M$131.30M$128.66M$11.54M$2.10M$13.47M$20.02M
    Total liabilities$138.49M$47.18M$264.39M$232.82M$98.07M$68.27M$120.06M$67.63M$39.67M$20.03M
    Short-term debt$2.33M$1.59M$2.06M$1.86M$1.67M$1.50M$4.67M$5.93M$5.17M$4.26M
    Long-term debt$100.56M$0$206.97MN/AN/AN/AN/AN/AN/AN/A
    Shareholder equity$7.99M$133.58M$43.50M$58.06M$52.38M$75.47M-$93.57M-$57.64M-$28.77M-$9.25M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$220.29M$154.22M$183.97M$146.48M$177.47M$212.12M$242.64M$180.77M$222.56M$258.42M$288.58M$307.89M
    Total liabilities$306.17M$207.20M$205.00M$138.49M$140.64M$143.56M$148.20M$47.18M$44.09M$39.05M$277.01M$264.39M
    Cash and equivalents$199.47M$133.34M$161.66M$124.22M$153.09M$186.57M$216.52M$152.60M$196.33M$226.86M$252.48M$277.92M
    Shareholder equity-$85.88M-$52.98M-$21.04M$7.99M$36.83M$68.56M$94.44M$133.58M$178.47M$219.37M$11.57M$43.50M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$129.79M-$194.41M-$193.31M-$115.30M-$80.32M-$47.97M-$32.08M-$23.09M-$18.75M-$18.11M
    Capital expenditures$31.00K$2.60M$4.59M$686.00K$864.00K$1.36M$1.81M$1.43M$1.34M$215.00K
    Free cash flow-$129.82M-$197.01M-$197.90M-$115.99M-$81.19M-$49.33M-$33.89M-$24.52M-$20.09M-$18.32M
    Dividends paidN/AN/AN/AN/AN/AN/AN/A$828.00K$1.38MN/A
    Share repurchasesN/AN/A$355.00KN/AN/AN/AN/AN/AN/AN/A
    Investing cash flow-$28.00K-$2.60M-$4.59M-$686.00K-$809.00K-$1.36M-$1.81M-$1.43M-$1.34M-$215.00K
    Financing cash flow$101.45M$71.68M$201.96M$258.55M$83.77M$166.46M$43.33M$13.15M$13.54M$28.77M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$34.60M-$29.92M-$38.03M-$30.12M-$33.82M-$29.95M-$35.90M-$43.72M-$30.28M-$57.36M-$63.05M-$56.82M
    Capital expenditures$29.00KN/A$0$0$10.00K$0$21.00K$16.00K$247.00K$1.22M$1.12M$3.44M
    Free cash flow-$34.63MN/A-$38.03M-$30.12M-$33.83M-$29.95M-$35.92M-$43.74M-$30.53M-$58.57M-$64.17M-$60.26M
    Last 12 quarters

    Frequently Asked Questions About INBX

    What is Inhibrx Biosciences' annual revenue?

    Inhibrx Biosciences reported revenue of $1.30M for the fiscal year ended Dec 31, 2025.

    How fast is Inhibrx Biosciences' revenue growing?

    Revenue was up 550.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -16.0%.

    Is Inhibrx Biosciences profitable?

    No. Inhibrx Biosciences reported net income of -$140.06M for the fiscal year ended Dec 31, 2025, with a net margin of -10773.5%.

    How much free cash flow does INBX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$129.79M minus capital expenditures of $31.00K produced free cash flow of -$129.82M.

    How much debt does Inhibrx Biosciences have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $100.56M, short-term debt of $2.33M and cash and equivalents of $124.22M.